Literature DB >> 8558528

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".

C J Aquino1, D R Armour, J M Berman, L S Birkemo, R A Carr, D K Croom, M Dezube, R W Dougherty, G N Ervin, M K Grizzle, J E Head, G C Hirst, M K James, M F Johnson, L J Miller, K L Queen, T J Rimele, D N Smith, E E Sugg.   

Abstract

Directed screening of compounds selected from the Glaxo registry file for contractile activity on the isolated guinea pig gallbladder (GPGB) identified a series of 1,5-benzodiazepines with peripheral cholecystokinin (CCK) receptor agonist activity. Agonist efficacy within this series was modulated by variation of substituents on the N1-anilinoacetamide moiety. Remarkably, a single methyl group confers agonist activity, with an N-isopropyl substituent providing optimal efficacy. Hydrophilic substituents on the anilino nitrogen abolish agonist activity or produce antagonists of CCK. In contrast, hydrophilic electron-donating groups at the para-position of the anilino ring enhance or maintain in vitro and in vivo agonist activity. Despite decreased affinity for the human CCK-A receptor, relative to CCK-8, some of these compounds are equipotent to CCK as anorectic agents in rats following intraperitoneal administration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558528     DOI: 10.1021/jm950626d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.

Authors:  S Nakamura; Y Yamamura; S Itoh; T Hirano; K Tsujimae; M Aoyama; K Kondo; H Ogawa; T Shinohara; K Kan; Y Tanada; S Teramoto; T Sumida; S Nakayama; K Sekiguchi; T Kambe; G Tsujimoto; T Mori; M Tominaga
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

2.  Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation.

Authors:  Alan S Kopin; Edward W McBride; Ci Chen; Roger M Freidinger; Duan Chen; Chun-Mei Zhao; Martin Beinborn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

3.  Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.

Authors:  Elizabeth M Hadac; Eric S Dawson; James W Darrow; Elizabeth E Sugg; Terry P Lybrand; Laurence J Miller
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

4.  Fluorescence polarization screening for allosteric small molecule ligands of the cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Erin E Cawston; Laurence J Miller
Journal:  Assay Drug Dev Technol       Date:  2011-03-11       Impact factor: 1.738

5.  Small-molecule agonists for the glucagon-like peptide 1 receptor.

Authors:  Lotte Bjerre Knudsen; Dan Kiel; Min Teng; Carsten Behrens; Dilip Bhumralkar; János T Kodra; Jens J Holst; Claus B Jeppesen; Michael D Johnson; Johannes Cornelis de Jong; Anker Steen Jorgensen; Tim Kercher; Jarek Kostrowicki; Peter Madsen; Preben H Olesen; Jacob S Petersen; Fritz Poulsen; Ulla G Sidelmann; Jeppe Sturis; Larry Truesdale; John May; Jesper Lau
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-09       Impact factor: 11.205

Review 6.  Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.

Authors:  Laurence J Miller; Aditya J Desai
Journal:  Trends Endocrinol Metab       Date:  2016-05-04       Impact factor: 12.015

7.  Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.

Authors:  Aditya J Desai; Maoqing Dong; Kaleeckal G Harikumar; Laurence J Miller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-02       Impact factor: 4.052

8.  Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.

Authors:  Aditya J Desai; Brad R Henke; Laurence J Miller
Journal:  Bioorg Med Chem Lett       Date:  2015-03-24       Impact factor: 2.823

9.  Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.

Authors:  Aditya J Desai; Polo C H Lam; Andrew Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; Laurence J Miller
Journal:  J Med Chem       Date:  2015-12-10       Impact factor: 7.446

Review 10.  Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor.

Authors:  Erin E Cawston; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.